Evidence map›Paper›PMID 40971064›Full record

ArticleOphthalmology and therapy2025

Does the Efficacy, Durability, and Safety of Faricimab for Diabetic Macular Edema in Randomized Trials Translate into Real-World Settings?

Tunde Peto, Stela Vujosevic, Veeral Sheth, Amanda Downey, Kara Gibson, Andreas Pollreisz

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Real-world outcomes of faricimab in treatment-naïve diabetic macular edema: The Middle East perspective.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tunde PetoSchool of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.ORCID http://orcid.org/0000-0001-6265-0381
Stela VujosevicEye Clinic, IRCCS MultiMedica, Milan, Italy.ORCID http://orcid.org/0000-0001-6773-9967
Veeral ShethUniversity Retina and Macula Associates, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-7467-9947
Amanda DowneyF. Hoffmann-La Roche Ltd., Mississauga, ON, Canada.
Kara GibsonRoche Products Ltd., Welwyn Garden City, UK.
Andreas PollreiszMedical University of Vienna, Vienna, Austria. andreas.pollreisz@meduniwien.ac.at.ORCID http://orcid.org/0000-0003-3902-239X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-angiopoietin-2Anti-vascular endothelial growth factorDiabetic macular edemaDiabetic retinopathyFaricimabReal-world data

Identifiers

PMID40971064
PMCPMC12534678

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.